Table 1.
Patients’ characteristics in the study population
| Patients characteristics | Value |
|---|---|
| Total no. of patients received at least 2 cycles of InLuDOTA PRRT | 468 |
| Sex (Males: Females) | 289:179 |
| Age: median, range in years | 45 years, 20–76 years |
| Symptomatic patients before InLuDOTA PRRT | 400 |
| Metastatic disease before InLuDOTA PRRT | 461 |
| Site of Primary Tumour | |
| Pancreatic | 142 |
| Small intestine | 112 |
| Large intestine | 42 |
| Stomach | 16 |
| Gall bladder | 9 |
| Kidney | 1 |
| Lung/mediastinum/thymus | 58 |
| Unknown primary site | 88 |
| Grade -WHO 2017 | |
| Grade 1 | 231 |
| Grade 2 | 207 |
| Grade 3 | 30 |
| Prior therapies | |
| Surgical resection of lesion | 162 |
| Chemotherapy | 122 |
| Somatostatin analogue therapy | 161 |
| External beam radiotherapy (EBRT) | 40 |
| Progressive disease prior to InLuDOTA PRRT | 322 |
| Doses and cycles of InLuDOTA PRRT patients received in this study | |
| Range of total cumulative dose of InLuDOTA PRRT patients received | 12.76 GBq to 42.4GBq |
| Average total cumulative dose of InLuDOTA PRRT patient received | 30 GBq |
| Range of total number of InLuDOTA PRRT cycles patient received | two to 7 cycles |
| Average number of InLuDOTA PRRT cycles patient received | five cycles |